Two-thirds of life science company executives use social networking or plan to on behalf of their companies, a recent Deloitte survey said. Thirty-five percent said they have no plans to do so.
Around 44% said they have an informal strategy for social networking that is not documented or fully supported by leadership, and 32% have no strategy at all.
Many cited FDA’s lack of clarity when asked what was holding them back. Thirty-eight percent said they’re waiting for FDA guidance on social networking before making any investment, while 28% said they’re waiting to see what return on investment other firms get.
From the January 01, 2011 Issue of MM+M - Medical Marketing and Media
